Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes
Qin Lü(Shanghai Jiao Tong University), Jean‐Jacques Rouby(Sorbonne Université), H Koch(Biognosys (Switzerland)), Michael P. Rudolf(Biognosys (Switzerland)), Charles‐Édouard Luyt(Inserm), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Philippe Eggimann(University Hospital of Lausanne), Bruno François(Inserm), Antonio Perez(Biognosys (Switzerland)), Michael Tamm(University of Basel), Jorge Garbino(University Hospital of Geneva), Erkan Mus(Biognosys (Switzerland)), Emmanuelle Mercier(Centre Hospitalier Universitaire de Tours), Michel Wolff(Université Paris Cité), Hedvika Lazar(Biognosys (Switzerland)), Jean Chastre(Sorbonne Université), Verena Gafner(Biognosys (Switzerland))
Cited by 90
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
International evidence-based recommendations for point-of-care lung ultrasound
|Intensive Care Medicine|2012|2.9k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
Ventilator-associated pneumonia in adults: a narrative review
|Intensive Care Medicine|2020|995
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976